Tenaya Therapeutics, Inc. TNYA
At closeNov 6, 2026, 8:10 AM EST
Pre-market · Nov 6, 8:10 AM ET
- YTD
- -55.62%
- 1 year
- -76.59%
- Market cap
- 72.03M
- EPS (ttm)
- -0.48
- Shares out
- 79.22M
- Forward P/E
- -1.28
- YTD return
- -55.62%
- 1-year return
- -76.59%
- Volume
- 7.50M
- Avg volume
- 2.83M
- Open
- 0.3847
- Previous close
- 0.3699
- Day's range
- 0.30 – 0.3855
- 52-week range
- 0.30 – 1.56
- Beta
- 2.35
- Analysts
- Strong Buy
- Price target
- 18.50 (+5754.4%)
- Earnings date
- Aug 8, 2024
YTD -0.4190 (-57.01%)
Key statistics
- Enterprise value
- 67.37M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -56.52M
- Total cash
- 79.47M
- Total debt
- 14.54M
- Return on equity
- -84.49%
- Short % of float
- 25.39%
- 50-day average
- 2.40
- 200-day average
- 3.26
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 18.50
- Target (high)
- 40.00
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.315.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.37 | -0.30 | +0.07 | +18.92% |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | -0.34 | +0.06 | +15.00% |
| May 14, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.43 | -0.40 | +0.03 | +6.98% |
| Mar 18, 2024 | Dec 1, 2023 | -0.45 | -0.40 | +0.05 | +11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Chardan Capital | main | Buy | Buy |
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 18, 2024 | Canaccord Genuity | main | Buy | Buy |
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenayatherapeutics.com
News
Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates 
Tenaya Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $1.697M Beat $800.000K Estimate 
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13 
Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3 
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
Your note
Sign in to keep a note on TNYA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI FARAZ | Chief Executive Officer | Sale | Aug 15, 2024 | 188,331 |
| COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| GOEDDEL DAVID V | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| HOEY TIMOTHY | Officer | Sale | Mar 4, 2024 | 245,346 |
| PATTERSON LEONE D. CPA | Chief Financial Officer | Stock Award(Grant) | Feb 22, 2024 | 95,755 |
| SAITO CHIHIRO | Officer | Sale | Nov 17, 2024 | 60,983 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Column Group LLC | 11.87% | 9,400,290 | 14.95M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.81% | 6,982,587 | 11.10M | Sep 29, 2024 |
| Casdin Capital, LLC | 8.50% | 6,732,971 | 10.71M | Sep 29, 2024 |
| Blackrock Inc. | 5.18% | 4,106,305 | 6.53M | Sep 29, 2024 |
| Vanguard Group Inc | 4.06% | 3,213,167 | 5.11M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.82% | 3,028,435 | 4.82M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 2.65% | 2,099,086 | 3.34M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.61% | 2,064,246 | 3.28M | Sep 29, 2024 |
| Fidelity Select Portfolios - Biotechnology | 2.20% | 1,746,113 | 2.78M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.80% | 1,428,719 | 2.27M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.87% | 691,525 | 1.10M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.72% | 567,023 | 901.57K | Aug 30, 2024 |